Approximately 100 Patients Enrolled; Data to be Reported in Second Half of 2012 - Stockhouse

"We are pleased to have completed enrollment of the Phase 2 portion of sapacitabine vs. low-dose cytarabine in elderly patients with AML or high risk MDS," said Professor Alan K. Burnett, MD, Department of Haematology, University of Cardiff and study chair.

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase 2/3 Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine - Yahoo Finance

Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module. You need to enable your browser cookies to view your most recent quotes.

Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and Highlights - Yahoo Finance

The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. Additionally ...

Cyclacel Reports First Quarter 2012 Financial Results - msnbc.com

In May 2012, announced completion of enrollment of the Phase 2 portion of the investigator-led, Phase 2/3 multicenter, randomized trial comparing sapacitabine to low dose cytarabine (the "Pick a Winner Programme / LI-1 Trial") in patients aged ...

Sunesis Pharmaceuticals, Inc. Earnings Conference Call (Q1 2012) - Yahoo! Finance

in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in platinum ...

An ASCO Bio-Pharma Catalyst Trade With A Promising Leukemia Drug - Seekingalpha.com

We are in the survival follow-up stage of two fully-enrolled clinical trials of vosaroxin: the Phase II portion of a Phase Ib/II trial of vosaroxin in combination with cytarabine for the treatment of patients with first relapsed or primary refractory AML ...

10-Q: SUNESIS PHARMACEUTICALS INC - Marketwatch

In December 2010, we commenced enrollment of a Phase 3, multi-national, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial.

Cyclacel Pharmaceuticals Inc. : Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting - 4-traders (press release)

Phase 2/3 study comparing sapacitabine to low dose cytarabine as front-line treatment of elderly patients with AML or high risk MDS unfit for intensive chemotherapy. Sapacitabine acts through a novel DNA single-strand breaking mechanism, leading to ...

Researchers Looking for Drug Candidates Tap into the Final Frontier: The Sea - Genetic Engineering News

These include the anticancer agent cytarabine, derived from a sponge, and ziconotide for severe pain based on a toxin derived from a marine snail. Additionally, Dr. Gerwick noted, 13 agents with a marine origin are currently in clinical trials.

PACIRA PHARMACEUTICALS, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - TMCnet

DepoCyt(e) is a sustained release liposomal formulation of the chemotherapeutic agent cytarabine and is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt(e) was granted accelerated approval by the FDA in 1999 and full ...